Ozone Layer and Health : the MDI issue

1
Ozone Layer and Health the MDI issue

• 24 January 2008
• Balaji Natarajan
• Compliance Assistance Programme
• OzonAction, UNEP DTIE

2
Coverage

• Overview of CFC MDI phaseout situation Asia and
  the Pacific region
• Awareness on CFC MDI phaseout in import dependent
  countries
• Inputs sought from participants

3
Overview of CFC MDI consumption in Asia and the
Pacific region

• Total estimated number of Asthma and COPD
  patients world wide is about 300 million. Asia
  Pacific regional estimates are expected to be
  about 100 million and are experiencing a growth
  rate of more than 20-25 per annum, as per
  industry sources.
• MDI use for asthma and other lung related
  diseases increasing due to increase in pollution
  levels. Prevalence varies from about 1 of
  population to more than 10 of population.
• Due to higher economic growth and increase in
  affordability, MDI sales is also increasing.
• CFC MDI manufacturing companies located in
  Bangladesh, China, India, Indonesia, Iran and
  Pakistan.
• A few companies (e.g., CIPLA (India), Beximco
  (Bangladesh) etc.) are already manufacturing and
  selling CFC free alternatives to CFC MDIs.

4
Production of CFC MDIs in the region

• Only 6 producers of CFC MDIs in the region.
• Projects to phaseout CFCs in most of the
  manufacturers under preparation or under
  implementation.
• MDI manufacturers, in general, produce other
  pharma products thus have an extensive reach
  through their medical representative network.
• They have interests in enhancing awareness on
  adoption of CFC free MDIs.

5
CFC MDI phaseout in countries dependent on
imports for MDIs

• Does not directly affect Montreal Protocol
  compliance status.
• Phaseout predominantly driven by supply situation
  of MDIs if key suppliers are producing CFC free
  alternatives to CFC based MDIs, then markets are
  adopting these alternatives.
• Very limited awareness programs taken up by
  Governments through their National Ozone Units on
  CFC MDI phaseout.
• Interfaces with Health Ministry, Drug Regulators
  and practitioners on MDI phaseout are evolving.
• Consumer awareness especially relating to OTC
  sales of medicines - may add to the momentum of
  adoption of CFC free alternatives.

6
QUESTIONS TO THE GROUP

• What kind of awareness products would be most
  effective (e.g., videos on usage of CFC free
  alternatives, phamplets, educational posters
  etc.).
• Suggestions on specific fora/ meetings that these
  awareness programs can be integrated with for
  greater out-reach.
• Areas where Government participate in the
  awareness programs.
• What kind of Regional initiatives would be
  helpful in these awareness campaigns.

7
QUESTIONS TO THE GROUP

• What kind of awareness products would be most
  effective (e.g., videos on usage of CFC free
  alternatives, phamplets, educational posters
  etc.).

8
QUESTIONS TO THE GROUP

• Suggestions on specific fora/ meetings that these
  awareness programs can be integrated with for
  greater out-reach.

9
QUESTIONS TO THE GROUP

• Areas where Government participate in the
  awareness programs.

10
QUESTIONS TO THE GROUP

• What kind of Regional initiatives would be
  helpful in these awareness campaigns.

11
Thank you